FDA is trying to take back the issue of the generic drug application backlog, attempting to reset a bloated definition that has painted the agency's review performance in a negative light.
“There’s a big gap between our formal GDUFA commitment on the backlog and what stakeholders expect on the other,” Keith Flanagan, director of the Office of Generic Drugs’ Office of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?